Skip to main content
SpringerLink
Log in

Use of 24-Hour Ambulatory Blood Pressure Monitoring to Assess Antihypertensive Efficacy

A Comparison of Olmesartan Medoxomil, Losartan Potassium, Valsartan, and Irbesartan

  • Original Research Article
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

Introduction: Goal rates, the percentage of patients with hypertension achieving recommended SBP/DBP, are a clinically important assessment of an antihypertensive agent’ efficacy. Twenty-four-hour ambulatory blood pressure monitoring (ABPM) allows accurate assessment of a patient’s hypertension and risk for cardiovascular events, and provides the most accurate measure of an antihypertensive agent’s efficacy throughout a 24-hour dosing interval.

Methods: A 12-week (4-week single-blind placebo run-in phase followed by an 8-week double-blind active treatment phase) randomized, parallel-group study reported that the recommended starting dose of the angiotensin II receptor antagonist (angiotensin receptor blocker; ARB) olmesartan medoxomil (Benicar™) 20 mg/day was more effective than starting doses of losartan potassium (Cozaar®) 50 mg/day, valsartan (Diovan®) 80 mg/day, or irbesartan (Avapro®) 150 mg/day in reducing cuff DBP in patients with essential hypertension. The present report includes analyses of secondary efficacy variables from this 12-week trial.

Results: The mean reduction in blood pressure from baseline to week 8 (end of treatment) was significantly greater with olmesartan medoxomil than with valsartan for all ABPM times analyzed (24 hours, daytime, night-time, and last 2 and 4 hours of monitoring). Statistical significance was reached for comparisons of oimesartan medoxomil with losartan potassium for a majority of times analyzed and with irbesartan for SBP in the last 4 hours of monitoring. Goal rates for accepted critical ambulatory blood pressure (ABP) values of < 130/80mm Hg for mean 24-hour ABP, <135/85mm Hg for mean daytime ABP, and <120/75mm Hg for mean night-time ABP were significantly greater for patients receiving olmesartan medoxomil than for those receiving losartan potassium or valsartan. Goal rates were numerically superior, but not statistically significant, to those achieved with irbesartan. Compared with losartan potassium or valsartan recipients, a significantly higher percentage of patients treated with olmesartan medoxomil achieved the 24-hour ABP goal of <130/85mm Hg. The last 2 and 4 hours of ABPM indicated that olmesartan medoxomil maintained larger mean decreases in blood pressure through the morning surge.

Discussion/Conclusion: ABP goal rates are a meaningful measure of antihypertensive efficacy. The effects on mean change from baseline in ABP and ABP goal rates after 8 weeks of treatment were numerically better, but not statistically significant, for olmesartan medoxomil than for irbesartan. However, olmesartan medoxomil was significantly more effective than losartan potassium or valsartan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Fig. 3
Table II
Table III
Fig. 4
Table IV

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42(6): 1206–52

    Article  PubMed  CAS  Google Scholar 

  2. Oparil S, Silfani TN, Walker JF. Role of angiotensin receptor blockers as monotherapy in reaching blood pressure goals. Am J Hypertens. In press

  3. Singer GM, Izhar M, Black HR. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension 2002 Oct; 40(4): 464–9

    Article  PubMed  CAS  Google Scholar 

  4. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension. N Engl J Med 2003 Jun 12; 348(24): 2407–15

    Article  PubMed  Google Scholar 

  5. Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension: Systolic Hypertension in Europe Trial Investigators. JAMA 1999 Aug 11; 282(6): 539–46

    Article  PubMed  CAS  Google Scholar 

  6. Mancia G, Zanchetti A, Agabiti-Rosei E, et al. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy: SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation 1997 Mar 18; 95(6): 1464–70

    Article  PubMed  CAS  Google Scholar 

  7. Gibbs CR, Murray S, Beevers DG. The clinical value of ambulatory blood pressure monitoring. Heart 1998 Feb; 79(2): 115–7

    PubMed  CAS  Google Scholar 

  8. White WB. Cardiovascular risk and therapeutic intervention for the early morning surge in blood pressure and heart rate. Blood Press Monit 2001 Apr; 6(2): 63–72

    Article  PubMed  CAS  Google Scholar 

  9. Muller JE, Tofler GH, Stone PH. Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 1989 Apr; 79(4): 733–43

    Article  PubMed  CAS  Google Scholar 

  10. Marler JR, Price TR, Clark GL, et al. Morning increase in onset of ischemic stroke. Stroke 1989 Apr; 20(4): 473–6

    Article  PubMed  CAS  Google Scholar 

  11. White WB. Circadian variation of blood pressure: clinical relevance and implications for cardiovascular chronotherapeutics. Blood Press Monit 1997 Dec; 2(1): 47–51

    PubMed  Google Scholar 

  12. McGrath BP. Ambulatory blood pressure monitoring. Med J Aust 2002 Jun 17; 176(12): 588–92

    PubMed  Google Scholar 

  13. Myers MG, Haynes RB, Rabkin SW. Canadian hypertension society guidelines for ambulatory blood pressure monitoring. Am J Hypertens 1999 Nov; 12 (11 Pt 1): 1149–57

    Article  PubMed  CAS  Google Scholar 

  14. O’Brien E, Coats A, Owens P, et al. Use and interpretation of ambulatory blood pressure monitoring: recommendations of the British Hypertension Society. BMJ 2000 Apr 22; 320(7242): 1128–34

    Article  PubMed  Google Scholar 

  15. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001 Sep–Oct; 3(5): 283–91, 318

    Article  CAS  Google Scholar 

  16. Hommel G. A stagewise rejective multiple test procedure based on a modified Bonferroni test. Biometrika 1988; 75: 383–6

    Article  Google Scholar 

  17. Byyny RL. Antihypertensive efficacy of the angiotensin II AT1-receptor antagonist losartan: results of a randomized, double-blind, placebo-controlled, parallel-group trial using 24-hour blood pressure monitoring. Ambulatory Blood Pressure Monitoring Study Group. Blood Press Suppl 1996; 2: 71–7

    PubMed  CAS  Google Scholar 

  18. Fogari R, Ambrosoli S, Corradi L, et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring: Irbesartan Multicenter Investigators Group. J Hypertens 1997 Dec; 15 (12 Pt 1): 1511–8

    Article  PubMed  CAS  Google Scholar 

  19. Neutel J, Weber M, Pool J, et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours. Clin Ther 1997 May–Jun; 19(3): 447–58; discussion 367–8

    Article  PubMed  CAS  Google Scholar 

  20. Neutel JM, Elliott WJ, Izzo TL, et al. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J Clin Hypertens (Greenwich) 2002 Sep–Oct; 4(5): 325–31

    Article  CAS  Google Scholar 

  21. Gillis JC, Markharn A. Irbesartan: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in the management of hypertension. Drugs 1997 Dec; 54(6): 885–902

    Article  PubMed  CAS  Google Scholar 

  22. Warner GT, Jarvis B. Olmesartan medoxomil. Drags 2002; 62(9): 1345–53; discussion 1354–6

    Article  CAS  Google Scholar 

  23. Chrysant SG, Marbury TC, Robinson IT). Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003 Jun; 17(6): 425–32

    Article  PubMed  CAS  Google Scholar 

  24. The Fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993 Jan 25; 153(2): 154–83

    Article  Google Scholar 

Download references

Acknowledgments

This study was supported by Sankyo Pharma Inc. The authors have no conflicts of interest directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Integrium, 14351 Myford Road, Tustin, CA, 92780, USA

    David H. G. Smith

  2. Memorial Research Medical Clinic, Long Beach, California, USA

    David H. G. Smith

  3. Sankyo Pharma Inc., Parsippany, New Jersey, USA

    Robert Dubiel & Michael Jones

Authors
  1. David H. G. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Dubiel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David H. G. Smith.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Smith, D.H.G., Dubiel, R. & Jones, M. Use of 24-Hour Ambulatory Blood Pressure Monitoring to Assess Antihypertensive Efficacy. Am J Cardiovasc Drugs 5, 41–50 (2005). https://doi.org/10.2165/00129784-200505010-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129784-200505010-00006

Keywords

Search

Navigation